Clinical trial · Interventional
myDC/pDC in Stage III Melanoma Patients
Myeloid and Plasmacytoid Blood Dendritic Cells for Immunotherapy of Stage III Melanoma Patients
NCT02574377CI-TRIAL-00053955completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an interventional study to test the immunogenicity of combined adjuvant myDC and pDC vaccination versus adjuvant myDC or pDC vaccination alone in stage III melanoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| A: myDC vaccination | Drug | — | UNRESOLVED |
| B: pDC vaccination | Drug | — | UNRESOLVED |
| C: combined myDC/pDC vaccination | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- A: myDC vaccination
- description
- intranodal injection with tumor peptide-loaded myeloid dendritic cells
- interventionNames
- Drug: A: myDC vaccination
- type
- EXPERIMENTAL
- label
- B: pDC vaccination
- description
- intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells
- interventionNames
- Drug: B: pDC vaccination
- type
- EXPERIMENTAL
- label
- C: combined myDC/pDC vaccination
- description
- intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * stage III melanoma * WHO performance status 0-1 * radical lymph node dissection is schedule or performed within 12 weeks prior to start of study treatment Exclusion Criteria: * irresectable disease * any concurrent adjuvant therapy * concomitant use of oral immunosuppressive drugs * autoimmune diseases
References
Publications (0)
Data not yet available
No reference posted for this study.